LinkedIn facebook twitter youtube
News archive
Recent news

There are currently a range of novel and chemotherapy drugs and drug combinations available and in development for the treatment of myeloma. However, as myeloma is a complex and individual cancer, not every treatment is suitable for each patient.

To explore solutions to address this issue, Myeloma Patients Europe (MPE) is participating in Horizon 2020 MMPredict.

Funded by the European Commission, this is a multi-stakeholder, pan-European project, aiming to develop a personalised medicine tool to predict the most effective treatment strategy for individual myeloma patients.

To explain the main goals of MMPredict, MPE has filmed a video with some partners working in the project consortium:

  • Erik Valent, Scientist and Junior Project leader, Skyline DX.
  • Ken Redekop, PhD Associate Professor, Institute for Medical Technology Assessment, Erasmus Universiteti Rotterdam.
  • Alessandra Laroca, MD, PhD Consultant Physician of the Division Haematology at the Department of Haematology-Oncology University Hospital Cittá della Scienza, Torino.



For further information, please visit the Horizon2020 website.

You can also find further information on the MPE website here or the MPE Q&A on this project.

Please email info@mpeurope.org if you have any questions or comments about Horizon2020 MMPredict or other programmes MPE is involved in.

Recent news

» Daratumumab approved for first line treatment in Israel

» Join MPE's webinar on doctor and patients’ perspectives on myeloma CAR-T

Leave a Reply

Your email address will not be published. Required fields are marked *

I accept the Privacy Policy